Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Acquisitions & Divestments: 2011-2025

Historic Change in Acquisitions & Divestments for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Sep 2025 value amounting to $101.8 million.

  • Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments rose 8.59% to $101.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $689.6 million, marking a year-over-year increase of 55.90%. This contributed to the annual value of $689.6 million for FY2025, which is 55.90% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments stood at $101.8 million, which was down 57.69% from $240.5 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $240.5 million for Q2 2025, and its period low was $13.1 million during Q1 2021.
  • In the last 3 years, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $106.6 million in 2023 and averaged $126.3 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments surged by 314.72% in 2021 and then slumped by 46.40% in 2023.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments stood at $38.3 million in 2021, then soared by 81.39% to $69.4 million in 2022, then surged by 92.31% to $133.5 million in 2023, then fell by 11.48% to $118.2 million in 2024, then increased by 8.59% to $101.8 million in 2025.
  • Its last three reported values are $101.8 million in Q3 2025, $240.5 million for Q2 2025, and $229.2 million during Q1 2025.